Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 235060, 25 pages
http://dx.doi.org/10.1155/2014/235060
Review Article

Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis

1Department of Health Sciences, School of Medicine, University of Milano Bicocca, Milan, Italy
2Endocrinology Department, Area Vasta N. 1, Cagli, Italy

Received 13 March 2014; Revised 17 June 2014; Accepted 18 June 2014; Published 23 July 2014

Academic Editor: Robert D. Murray

Copyright © 2014 Vittorio Locatelli and Vittorio E. Bianchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Bouillon and A. Prodonova, “Growth hormone deficiency and peak bone mass,” Journal of Pediatric Endocrinology & Metabolism, vol. 13, supplement 6, pp. 1327–1336, 2000. View at Google Scholar · View at Scopus
  2. A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama, “Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2423–2428, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Giustina, G. Mazziotti, and E. Canalis, “Growth hormone, insulin-like growth factors, and the skeleton,” Endocrine Reviews, vol. 29, no. 5, pp. 535–559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Barrett-Connor and D. Goodman-Gruen, “Gender differences in insulin-like growth factor and bone mineral density association in old age: the rancho Bernardo study,” Journal of Bone and Mineral Research, vol. 13, no. 8, pp. 1343–1349, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Langlois, C. J. Rosen, M. Visser et al., “Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 12, pp. 4257–4262, 1998. View at Google Scholar · View at Scopus
  6. J. A. M. J. L. Janssen, H. Burger, R. P. Stolk et al., “Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women,” European Journal of Endocrinology, vol. 138, no. 6, pp. 627–632, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Johansson, A. Forslund, L. Hambraeus, W. F. Blum, and S. Ljunghall, “Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men,” Journal of Bone and Mineral Research, vol. 9, no. 6, pp. 915–921, 1994. View at Google Scholar · View at Scopus
  8. T. Sugimoto, K. Nishiyama, F. Kuribayashi, and K. Chihara, “Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures,” Journal of Bone and Mineral Research, vol. 12, no. 8, pp. 1272–1279, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Garnero, E. Sornay-Rendu, and P. D. Delmas, “Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women,” The Lancet, vol. 355, no. 9207, pp. 898–899, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Ohlsson, D. Mellström, D. Carlzon et al., “Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study,” Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 865–872, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, and T. Sugimoto, “Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus,” Osteoporosis International, vol. 18, no. 12, pp. 1675–1681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Ebeling, L. M. Atley, J. R. Guthrie et al., “Bone turnover markers and bone density across the menopausal transition,” Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 9, pp. 3366–3371, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Y. Ho, W. S. Evans, R. M. Blizzard et al., “Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations,” Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 1, pp. 51–58, 1987. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Szulc, M. O. Joly-Pharaboz, F. Marchand, and P. D. Delmas, “Insulin-like growth factor I is a determinant of Hip bone mineral density in men less than 60 years of age: MINOS study,” Calcified Tissue International, vol. 74, no. 4, pp. 322–329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Seeman, “Estrogen, androgen, and the pathogenesis of bone fragility in women and men,” Current Osteoporosis Reports, vol. 2, no. 3, pp. 90–96, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Almeida, L. Han, M. Martin-Millan et al., “Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 27285–27297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Yakar, H. Courtland, and D. Clemmons, “IGF-1 and bone: new discoveries from mouse models,” Journal of Bone and Mineral Research, vol. 25, no. 12, pp. 2543–2552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Fritton, K. B. Emerton, H. Sun et al., “Growth hormone protects against ovariectomy-induced bone loss in states of low circulating Insulin-like Growth Factor (IGF-1),” Journal of Bone and Mineral Research, vol. 25, no. 2, pp. 235–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Giustina and J. D. Veldhuis, “Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human,” Endocrine Reviews, vol. 19, no. 6, pp. 717–797, 1998. View at Google Scholar · View at Scopus
  20. J. R. Florini, D. Z. Ewton, and S. A. Coolican, “Growth hormone and the insulin-like growth factor system in myogenesis,” Endocrine Reviews, vol. 17, no. 5, pp. 481–517, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Feld and R. Hirschberg, “Insulinlike growth factor I and the kidney,” Trends in Endocrinology & Metabolism, vol. 7, no. 3, pp. 85–93, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Goldspink and S. D. R. Harridge, “Growth factors and muscle ageing,” Experimental Gerontology, vol. 39, no. 10, pp. 1433–1438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Aberg, “Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis,” Endocrine Development, vol. 17, pp. 63–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Ohlsson, B. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg, “Growth hormone and bone,” Endocrine Reviews, vol. 19, no. 1, pp. 55–79, 1998. View at Google Scholar · View at Scopus
  25. M. Ballesteros, K. Leung, R. J. M. Ross, T. P. Iismaa, and K. K. Y. Ho, “Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2865–2871, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Yakar, J.-L. Liu, B. Stannard et al., “Normal growth and development in the absence of hepatic insulin-like growth factor I,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7324–7329, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-P. Liu, J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis, “Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r),” Cell, vol. 75, no. 1, pp. 59–72, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Sjögren, J. Liu, K. Blad et al., “Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 7088–7092, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Holly and C. Perks, “The role of insulin-like growth factor binding proteins,” Neuroendocrinology, vol. 83, no. 3-4, pp. 154–160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. C. J. Rosen, L. R. Donahue, and S. J. Hunter, “Insulin-like growth factors and bone: the osteoporosis connection,” Proceedings of the Society for Experimental Biology and Medicine, vol. 206, no. 2, pp. 83–102, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Goldenberg and A. Barkan, “Factors regulating growth hormone secretion in humans,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 1, pp. 37–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. J. I. Jones and D. R. Clemmons, “Insulin-like growth factors and their binding proteins: biological actions,” Endocrine Reviews, vol. 16, no. 1, pp. 3–34, 1995. View at Google Scholar · View at Scopus
  33. C. M. Bagi, R. Brommage, L. Deleon, S. Adams, D. Rosen, and A. Sommer, “Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats,” Journal of Bone and Mineral Research, vol. 9, no. 8, pp. 1301–1312, 1994. View at Google Scholar · View at Scopus
  34. C. Carter-Su and L. S. Smit, “Signaling via JAK tyrosine kinases: growth hormone receptor as a model system,” Recent Progress in Hormone Research, vol. 53, pp. 61–83, 1998. View at Google Scholar · View at Scopus
  35. S. F. Ahmed and C. Farquharson, “The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins,” Journal of Endocrinology, vol. 206, no. 3, pp. 249–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. V. E. Macrae, S. Horvat, S. C. Pells et al., “Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice,” Journal of Cellular Physiology, vol. 218, no. 2, pp. 276–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Bang, M. Westgren, J. Schwander, W. F. Blum, R. G. Rosenfeld, and M. Stangenberg, “Ontogeny of insulin-like growth factor-binding protein-1, -2, and -3: quantitative measurements by radioimmunoassay in human fetal serum,” Pediatric Research, vol. 36, no. 4, pp. 528–536, 1994. View at Publisher · View at Google Scholar · View at Scopus
  38. G. P. Baumann, “Growth hormone isoforms,” Growth Hormone and IGF Research, vol. 19, no. 4, pp. 333–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Frystyk, P. Freda, and D. R. Clemmons, “The current status of IGF-I assays–a 2009 update,” Growth Hormone & IGF Research, vol. 20, no. 1, pp. 8–18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Bancos, A. Algeciras-Schimnich, W. W. Woodmansee et al., “Determination of nadir growth hormone concentration cutoff in patients with acromegaly,” Endocrine Practice, vol. 19, no. 6, pp. 937–945, 2013. View at Google Scholar
  41. A. W. van Toorenenbergen, “Between-laboratory quality control of automated analysis of IgG antibodies against Aspergillus fumigatus,” Diagnostic Microbiology and Infectious Disease, vol. 74, no. 3, pp. 278–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. D. Faix, “Principles and pitfalls of free hormone measurements,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 27, no. 5, pp. 631–645, 2013. View at Google Scholar
  43. W. D. Salmon Jr. and W. H. Daughaday, “A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro,” The Journal of Laboratory and Clinical Medicine, vol. 49, no. 6, pp. 825–836, 1957. View at Google Scholar · View at Scopus
  44. N. L. Schlechter, S. M. Russell, S. Greenberg, E. M. Spencer, and C. S. Nicoll, “A direct growth effect of growth hormone in rat hindlimb shown by arterial infusion,” American Journal of Physiology—Endocrinology and Metabolism, vol. 250, no. 3, part 1, pp. E231–E235, 1986. View at Google Scholar · View at Scopus
  45. H. Green, M. Morikawa, and T. Nixon, “A dual effector theory of growth-hormone action,” Differentiation, vol. 29, no. 3, pp. 195–198, 1985. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Lindahl, J. Isgaard, A. Nilsson, and O. G. P. Isaksson, “Growth hormone potentiates colony formation of epiphyseal chondrocytes in suspension culture,” Endocrinology, vol. 118, no. 5, pp. 1843–1848, 1986. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Ohlsson, A. Nilsson, O. Isaksson, and A. Lindahl, “Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 20, pp. 9826–9830, 1992. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Kassem, L. Mosekilde, and E. F. Eriksen, “Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro,” Growth Regulation, vol. 4, no. 3, pp. 131–135, 1994. View at Google Scholar · View at Scopus
  49. A. Nilsson, D. Swolin, S. Enerback, and C. Ohlsson, “Expression of functional growth hormone receptors in cultured human osteoblast-like cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 12, pp. 3483–3488, 1995. View at Google Scholar · View at Scopus
  50. M. Ernst and G. A. Rodan, “Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3,” Endocrinology, vol. 127, no. 2, pp. 807–814, 1990. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. Laron and B. Klinger, “IGF-I treatment of adult patients with Laron syndrome: preliminary results,” Clinical Endocrinology, vol. 41, no. 5, pp. 631–638, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. M. B. Ranke, M. O. Savage, P. G. Chatelain et al., “Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results,” Hormone Research, vol. 44, no. 6, pp. 253–264, 1995. View at Publisher · View at Google Scholar · View at Scopus
  53. J. L. Walker, J. J. Van Wyk, and L. E. Underwood, “Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type),” Journal of Pediatrics, vol. 121, no. 4, pp. 641–646, 1992. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Guevara-Aguirre, A. L. Rosenbloom, O. Vasconez et al., “Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 2, pp. 629–633, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. P. F. Collett-Solberg, M. Misra, and Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine, “The role of recombinant human insulin-like growth factor-I in treating children with short stature,” Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 10–18, 2008. View at Google Scholar
  56. C. J. Rosen and J. P. Bilezikian, “Clinical review 123: anabolic therapy for osteoporosis,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 3, pp. 957–964, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. O. G. P. Isaksson, J. O. Jansson, and I. A. M. Gause, “Growth hormone stimulates longitudinal bone growth directly,” Science, vol. 216, no. 4551, pp. 1237–1239, 1982. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Isgaard, C. Moller, O. G. P. Isaksson, A. Nilsson, L. S. Mathews, and G. Norstedt, “Regulation of insulin-like growth factor messenger ribonucleic acid in rat growth plate by growth hormone,” Endocrinology, vol. 122, no. 4, pp. 1515–1520, 1988. View at Publisher · View at Google Scholar · View at Scopus
  59. E. B. Hunziker, J. Wagner, and J. Zapf, “Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo,” Journal of Clinical Investigation, vol. 93, no. 3, pp. 1078–1086, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. H. P. Guler, J. Zapf, E. Scheiwiller, and E. R. Froesch, “Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 13, pp. 4889–4893, 1988. View at Publisher · View at Google Scholar · View at Scopus
  61. S. R. Kupfer, L. E. Underwood, R. C. Baxter, and D. R. Clemmons, “Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously,” Journal of Clinical Investigation, vol. 91, no. 2, pp. 391–396, 1993. View at Publisher · View at Google Scholar · View at Scopus
  62. P. J. Fielder, D. L. Mortensen, P. Mallet, B. Carlsson, R. C. Baxter, and R. G. Clark, “Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats,” Endocrinology, vol. 137, no. 5, pp. 1913–1920, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. S. J. Hazel, C. M. Gillespie, R. J. Moore, R. G. Clark, K. F. Jureidini, and A. A. Martin, “Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination,” Kidney International, vol. 46, no. 1, pp. 58–68, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. N. A. Sims, P. Clément-Lacroix, F. da Ponte et al., “Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5,” The Journal of Clinical Investigation, vol. 106, no. 9, pp. 1095–1103, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Courtland, S. Elis, Y. Wu et al., “Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner,” PLoS ONE, vol. 6, no. 3, Article ID e14762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Laviola, A. Natalicchio, S. Perrini, and F. Giorgino, “Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 295, no. 5, pp. E991–E999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Yakar, E. Canalis, H. Sun et al., “Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions,” Journal of Bone and Mineral Research, vol. 24, no. 8, pp. 1481–1492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Zhang, S. Xuan, M. L. Bouxsein et al., “Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization,” Journal of Biological Chemistry, vol. 277, no. 46, pp. 44005–44012, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Yakar, C. J. Rosen, W. G. Beamer et al., “Circulating levels of IGF-1 directly regulate bone growth and density,” Journal of Clinical Investigation, vol. 110, no. 6, pp. 771–781, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Uronen-Hansson, M. L. Allen, E. Lichtarowicz-Krynska et al., “Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood,” Growth Hormone and IGF Research, vol. 13, no. 5, pp. 282–286, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Renier, I. Clément, A. C. Desfaits, and A. Lambert, “Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-α production,” Endocrinology, vol. 137, no. 11, pp. 4611–4618, 1996. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Wolf, S. Bohm, M. Brand, and G. Kreymann, “Proinflammatory cytokines interleukin 1-β and tumor necrosis factor α inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells,” European Journal of Endocrinology, vol. 135, no. 6, pp. 729–737, 1996. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Swolin and C. Ohlsson, “Growth hormone increases interleukin-6 produced by human osteoblast- like cells,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 12, pp. 4329–4333, 1996. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Yamaguchi, M. Kanatani, M. Yamauchi et al., “Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women,” Calcified Tissue International, vol. 78, no. 1, pp. 18–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Boonen, S. Mohan, J. Dequeker et al., “Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis,” Journal of Bone and Mineral Research, vol. 14, no. 12, pp. 2150–2158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Seck, C. Scheidt-Nave, G. Leidig-Bruckner, R. Ziegler, and J. Pfeilschifter, “Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women,” Clinical Endocrinology, vol. 55, no. 1, pp. 101–106, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. G. E. Krassas, P. Papadopoulou, G. Koliakos, T. Konstantinidis, and K. Kalothetou, “Growth hormone, insulin growth factor-1, and IGF binding protein-3 axis relationship with bone mineral density among healthy men,” Archives of Andrology, vol. 49, no. 3, pp. 191–199, 2003. View at Google Scholar · View at Scopus
  78. P. M. Yamada and K. W. Lee, “Perspectives in mammalian IGFBP-3 biology: local vs. systemic action,” The American Journal of Physiology—Cell Physiology, vol. 296, no. 5, pp. C954–C976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. O. Ali, P. Cohen, and K.-W. Lee, “Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule,” Hormone and Metabolic Research, vol. 35, no. 11-12, pp. 726–733, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Benini, M. Zuntini, M. C. Manara et al., “Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma,” International Journal of Cancer, vol. 119, no. 5, pp. 1039–1046, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. I. Niemann, A. Hannemann, M. Nauck et al., “The association between insulin-like growth factor I and bone turnover markers in the general adult population,” Bone, vol. 56, no. 1, pp. 184–190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. S. C. Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Beato and J. Klug, “Steroid hormone receptors: an update,” Human Reproduction Update, vol. 6, no. 3, pp. 225–236, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. S. C. Manolagas, C. A. O'Brien, and M. Almeida, “The role of estrogen and androgen receptors in bone health and disease,” Nature Reviews Endocrinology, vol. 9, no. 12, pp. 699–712, 2013. View at Google Scholar
  85. D. S. Colvard, E. F. Eriksen, P. E. Keeting et al., “Identification of androgen receptors in normal human osteoblast-like cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 3, pp. 854–857, 1989. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Ohlsson and L. V. Vandenput, “The role of estrogens for male bone health,” European Journal of Endocrinology, vol. 160, no. 6, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Kawano, H. Kawaguchi, and S. Kato, “Bone metabolism in androgen receptor-deficient mice,” Clinical Calcium, vol. 13, no. 11, pp. 1443–1445, 2003. View at Google Scholar
  88. A. J. Notini, J. F. McManus, A. Moore et al., “Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice,” Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 347–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Callewaert, M. Sinnesael, E. Gielen, S. Boonen, and D. Vanderschueren, “Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading,” Journal of Endocrinology, vol. 207, no. 2, pp. 127–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Kousteni, T. Bellido, L. I. Plotkin et al., “Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity,” Cell, vol. 104, no. 5, pp. 719–730, 2001. View at Google Scholar · View at Scopus
  91. D. J. Benz, M. R. Haussler, M. A. Thomas, B. Speelman, and B. S. Komm, “High-affinity androgen binding and androgenic regulation of α1(I)-procollagen and transforming growth factor-β steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells,” Endocrinology, vol. 128, no. 6, pp. 2723–2730, 1991. View at Publisher · View at Google Scholar · View at Scopus
  92. J. P. Bilezikian, A. Morishima, J. Bell, and M. M. Grumbach, “Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency,” The New England Journal of Medicine, vol. 339, no. 9, pp. 599–603, 1998. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Coxam, B. M. Bowman, M. Mecham, C. M. Roth, M. A. Miller, and S. C. Miller, “Effects of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats,” Bone, vol. 19, no. 2, pp. 107–114, 1996. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Tomkinson, J. Reeve, R. W. Shaw, and B. S. Noble, “The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 9, pp. 3128–3135, 1997. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Martin-Millan, M. Almeida, E. Ambrogini et al., “The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone,” Molecular Endocrinology, vol. 24, no. 2, pp. 323–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. H. Windahl, L. Saxon, A. E. Börjesson et al., “Estrogen receptor-α is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2,” Journal of Bone and Mineral Research, vol. 28, no. 2, pp. 291–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley, “The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1032–1037, 2000. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Kawano, T. Sato, T. Yamada et al., “Suppressive function of androgen receptor in bone resorption,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 16, pp. 9416–9421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. K. M. Wiren, A. A. Semirale, X. W. Zhang et al., “Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis : a model for compartment-specific androgen action in the skeleton,” Bone, vol. 43, no. 3, pp. 440–451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Khosla, M. J. Oursler, and D. G. Monroe, “Estrogen and the skeleton,” Trends in Endocrinology and Metabolism, vol. 23, no. 11, pp. 576–581, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Falahati-Nini, B. L. Riggs, E. J. Atkinson, W. M. O'Fallon, R. Eastell, and S. Khosla, “Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1553–1560, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Mosekilde, J. S. Thomsen, P. B. Orhii, and D. N. Kalu, “Growth hormone increases vertebral and femoral bone strength in osteopenic, ovariectomized, aged rats in a dose-dependent and site-specific manner,” Bone, vol. 23, no. 4, pp. 343–352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Kasukawa, L. Stabnov, N. Miyakoshi, D. J. Baylink, and S. Mohan, “Insulin-like growth factor I effect on the number of osteoblast progenitors is impaired in ovariectomized mice,” Journal of Bone and Mineral Research, vol. 17, no. 9, pp. 1579–1587, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. J. K. Yeh, M. Chen, and J. F. Aloia, “Effects of estrogen and growth hormone on skeleton in the ovariectomized rat with hypophysectomy,” The American Journal of Physiology —Endocrinology and Metabolism, vol. 273, no. 4, pp. E734–E742, 1997. View at Google Scholar · View at Scopus
  105. L. S. Kidder, I. U. Schmidt, G. L. Evans, and R. T. Turner, “Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats,” Calcified Tissue International, vol. 61, no. 4, pp. 327–335, 1997. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Abe, J. W. M. Chow, J. M. Lean, and T. J. Chambers, “Estrogen does not restore bone lost after ovariectomy in the rat,” Journal of Bone and Mineral Research, vol. 8, no. 7, pp. 831–838, 1993. View at Google Scholar · View at Scopus
  107. G. K. Wakley, G. L. Evans, and R. T. Turner, “Short-term effects of high dose estrogen on tibiae of growing male rats,” Calcified Tissue International, vol. 60, no. 1, pp. 37–42, 1997. View at Publisher · View at Google Scholar · View at Scopus
  108. J. D. Veldhuis, J. Frystyk, A. Iranmanesh, and H. Ørskov, “Testosterone and estradiol regulate free insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP-1), and dimeric IGF-I/IGFBP-1 concentrations,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2941–2947, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. A. J. Weissberger, K. K. Ho, and L. Lazarus, “Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 2, pp. 374–381, 1991. View at Publisher · View at Google Scholar · View at Scopus
  110. L. Vandenput, S. Boonen, E. Van Herck, J. V. Swinnen, R. Bouillon, and D. Vanderschueren, “Evidence from the aged orchidectomized male rat model that 17β-estradiol is a more effective bone-sparing and anabolic agent than 5α-dihydrotestosterone,” Journal of Bone and Mineral Research, vol. 17, no. 11, pp. 2080–2086, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. J. J. Christiansen, S. Fisker, C. H. Gravholt et al., “Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I,” European Journal of Endocrinology, vol. 152, no. 5, pp. 719–726, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson, “Androgens and bone,” Endocrine Reviews, vol. 25, no. 3, pp. 389–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. C. H. Kasperk, J. E. Wergedal, J. R. Farley, T. A. Linkhart, R. T. Turner, and D. J. Baylink, “Androgens directly stimulate proliferation of bone cells in vitro,” Endocrinology, vol. 124, no. 3, pp. 1576–1578, 1989. View at Publisher · View at Google Scholar · View at Scopus
  114. L. X. Bi, K. M. Wiren, X. W. Zhang et al., “The effect of oxandrolone treatment on human osteoblastic cells,” Journal of Burns and Wounds, vol. 6, article e4, 2007. View at Google Scholar
  115. K. Venken, K. De Gendt, S. Boonen et al., “Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model,” Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 576–585, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. G. Prakasam, J. K. Yeh, M. Chen, M. Castro-Magana, C. T. Liang, and J. F. Aloia, “Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats,” Bone, vol. 24, no. 5, pp. 491–497, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. A. J. Weissberger and K. K. Y. Ho, “Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 6, pp. 1407–1412, 1993. View at Publisher · View at Google Scholar · View at Scopus
  118. H. K. Gleeson and S. M. Shalet, “Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness,” Clinical Endocrinology, vol. 70, no. 1, pp. 109–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. D. Vanderschueren, S. Boonen, A. G. H. Ederveen et al., “Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model,” Bone, vol. 27, no. 5, pp. 611–617, 2000. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Vanderschueren, E. Van Herck, A. M. H. Suiker, W. J. Visser, L. P. C. Schot, and R. Bouillon, “Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency,” Endocrinology, vol. 130, no. 5, pp. 2906–2916, 1992. View at Publisher · View at Google Scholar · View at Scopus
  121. A. E. Kearns and S. Khosla, “Potential anabolic effects of androgens on bone,” Mayo Clinic Proceedings, vol. 79, no. 4, pp. S14–S18, 2004. View at Google Scholar · View at Scopus
  122. C. J. Hobbs, S. R. Plymate, C. J. Rosen, and R. A. Adler, “Testosterone administration increases insulin-like growth factor-I levels in normal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 77, no. 3, pp. 776–779, 1993. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Liu, G. R. Merriam, and R. J. Sherins, “Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with isolated hypogonadotropic hypogonadism,” Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 4, pp. 651–656, 1987. View at Publisher · View at Google Scholar · View at Scopus
  124. J. O. L. Jørgensen, N. Vahl, T. B. Hansen et al., “Determinants of serum insulin-like growth factor I in growth hormone deficient adults as compared to healthy subjects,” Clinical Endocrinology, vol. 48, no. 4, pp. 479–486, 1998. View at Publisher · View at Google Scholar · View at Scopus
  125. C. Chiang, M. Chiu, A. J. Moore et al., “Mineralization and bone resorption are regulated by the androgen receptor in male mice,” Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 621–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. T. L. Andersen, T. E. Sondergaard, K. E. Skorzynska et al., “A physical mechanism for coupling bone resorption and formation in adult human bone,” The American Journal of Pathology, vol. 174, no. 1, pp. 239–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Kassem, W. Blum, J. Ristelli, L. Mosekilde, and E. F. Eriksen, “Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro,” Calcified Tissue International, vol. 52, no. 3, pp. 222–226, 1993. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Brixen, M. Kassem, H. K. Nielsen, A. G. Loft, A. Flyvbjerg, and L. Mosekilde, “Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study,” Journal of Bone and Mineral Research, vol. 10, no. 12, pp. 1865–1874, 1995. View at Google Scholar · View at Scopus
  129. V. Krishnan, H. U. Bryant, and O. A. MacDougald, “Regulation of bone mass by Wnt signaling,” Journal of Clinical Investigation, vol. 116, no. 5, pp. 1202–1209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. H. Clevers, “Wnt/β-catenin signaling in development and disease,” Cell, vol. 127, no. 3, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. M. F. Cole, S. E. Johnstone, J. J. Newman, M. H. Kagey, and R. A. Young, “Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells,” Genes and Development, vol. 22, no. 6, pp. 746–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Canalis, V. Deregowski, R. C. Pereira, and E. Gazzerro, “Signals that determine the fate of osteoblastic cells,” Journal of Endocrinological Investigation, vol. 28, no. 8, pp. 3–7, 2005. View at Google Scholar · View at Scopus
  133. M. Takeuchi, H. Kakushi, and M. Tohkin, “Androgens directly stimulate mineralization and increase androgen receptors in human osteoblast-like osteosarcoma cells,” Biochemical and Biophysical Research Communications, vol. 204, no. 2, pp. 905–911, 1994. View at Publisher · View at Google Scholar · View at Scopus
  134. P. Hou, T. Sato, W. Hofstetter, and N. T. Foged, “Identification and characterization of the insulin-like growth factor I receptor in mature rabbit osteoclasts,” Journal of Bone and Mineral Research, vol. 12, no. 4, pp. 534–540, 1997. View at Publisher · View at Google Scholar · View at Scopus
  135. T. Niu and C. J. Rosen, “The insulin-like growth factor-I gene and osteoporosis: a critical appraisal,” Gene, vol. 361, no. 1-2, pp. 38–56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. G. Mazziotti, A. Bianchi, S. Bonadonna et al., “Prevalence of vertebral fractures in men with acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 12, pp. 4649–4655, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. T. L. McCarthy and M. Centrella, “Regulation of IGF activity in bone,” Advances in Experimental Medicine and Biology, vol. 343, pp. 407–414, 1993. View at Google Scholar · View at Scopus
  138. D. P. Bichell, P. Rotwein, and T. L. McCarthy, “Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: Evidence for transcriptional control,” Endocrinology, vol. 133, no. 3, pp. 1020–1028, 1993. View at Google Scholar · View at Scopus
  139. E. Canalis, M. Centrella, W. Burch, and T. L. McCarthy, “Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures,” Journal of Clinical Investigation, vol. 83, no. 1, pp. 60–65, 1989. View at Publisher · View at Google Scholar · View at Scopus
  140. T. L. Mccarthy, M. Centrella, L. G. Raisz, and E. Canalis, “Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone,” Endocrinology, vol. 128, no. 6, pp. 2895–2900, 1991. View at Publisher · View at Google Scholar · View at Scopus
  141. R. M. Locklin, S. Khosla, R. T. Turner, and B. L. Riggs, “Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone,” Journal of Cellular Biochemistry, vol. 89, no. 1, pp. 180–190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  142. T. Ishizuya, S. Yokose, M. Hori et al., “Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells,” Journal of Clinical Investigation, vol. 99, no. 12, pp. 2961–2970, 1997. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Kassem and P. J. Marie, “Senescence-associated intrinsic mechanisms of osteoblast dysfunctions,” Aging Cell, vol. 10, no. 2, pp. 191–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. S. Amin, B. L. Riggs, L. J. Melton III, S. J. Achenbach, E. J. Atkinson, and S. Khosla, “High serum IGFBP-2 is predictive of increased bone turnover in aging men and women,” Journal of Bone and Mineral Research, vol. 22, no. 6, pp. 799–807, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. D. J. DiGirolamo, A. Mukherjee, K. Fulzele et al., “Mode of growth hormone action in osteoblasts,” The Journal of Biological Chemistry, vol. 282, no. 43, pp. 31666–31674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. C. T. Rubin, S. D. Bain, and K. J. McLeod, “Suppression of the osteogenic response in the aging skeleton,” Calcified Tissue International, vol. 50, no. 4, pp. 306–313, 1992. View at Publisher · View at Google Scholar · View at Scopus
  147. S. L. Bass, P. Eser, and R. Daly, “The effect of exercise and nutrition on the mechanostat,” Journal of Musculoskeletal Neuronal Interactions, vol. 5, no. 3, pp. 239–254, 2005. View at Google Scholar · View at Scopus
  148. J. P. Bonjour, “Protein intake and bone health,” International Journal for Vitamin and Nutrition Research, vol. 81, no. 2-3, pp. 134–142, 2011. View at Publisher · View at Google Scholar
  149. A. Simkin, J. Ayalon, and I. Leichter, “Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women,” Calcified Tissue International, vol. 40, no. 2, pp. 59–63, 1987. View at Publisher · View at Google Scholar · View at Scopus
  150. G. A. Kelley and K. S. Kelley, “Exercise and bone mineral density at the femoral neck in postmenopausal women: a meta-analysis of controlled clinical trials with individual patient data,” American Journal of Obstetrics and Gynecology, vol. 194, no. 3, pp. 760–767, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. M. Martyn-St James and S. Carroll, “A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes,” British Journal of Sports Medicine, vol. 43, no. 12, pp. 898–908, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. K. T. Borer, “Physical activity in the prevention and amelioration of osteoporosis in women: Interaction of mechanical, hormonal and dietary factors,” Sports Medicine, vol. 35, no. 9, pp. 779–830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. K. Landin-Wilhelmsen, P. A. Lundberg, G. Lappas, and L. Wilhelmsen, “Insulin-like growth factor I levels in healthy adults,” Hormone Research, vol. 62, supplement 1, pp. 8–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. A. E. Bennett, H. W. Wahner, B. L. Riggs, and R. L. Hintz, “Insulin-like growth factors I and II: aging and bone density in women,” Journal of Clinical Endocrinology and Metabolism, vol. 59, no. 4, pp. 701–704, 1984. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Callewaert, K. Venken, J. J. Kopchick et al., “Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models,” Journal of Bone and Mineral Research, vol. 25, no. 3, pp. 617–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. Y. Wu, H. Sun, J. Basta-Pljakic et al., “Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor,” Journal of Bone and Mineral Research, vol. 28, no. 7, pp. 1575–1586, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. S. Bonadonna, A. Burattin, M. Nuzzo et al., “Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects,” European Journal of Endocrinology, vol. 152, no. 2, pp. 199–205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  158. S. C. Manolagas and R. S. Weinstein, “New developments in the pathogenesis and treatment of steroid-induced osteoporosis,” Journal of Bone and Mineral Research, vol. 14, no. 7, pp. 1061–1066, 1999. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Berneis, M. Oehri, M. Kraenzlin, and U. Keller, “Effects of IGF-I combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man,” Journal of Endocrinology, vol. 162, no. 2, pp. 259–264, 1999. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Melmed, “Acromegaly,” The New England Journal of Medicine, vol. 322, no. 14, pp. 966–977, 1990. View at Google Scholar
  161. S. Ezzat, S. Melmed, D. Endres, D. R. Eyre, and F. R. Singer, “Biochemical assessment of bone formation and resorption in acromegaly,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 6, pp. 1452–1457, 1993. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Marazuela, B. Astigarraga, M. J. Tabuenca, J. Estrada, F. Marin, and T. Lucas, “Serum bone Gla protein as a marker of bone turnover in acromegaly,” Calcified Tissue International, vol. 52, no. 6, pp. 419–421, 1993. View at Publisher · View at Google Scholar · View at Scopus
  163. A. Scillitani, C. Battista, I. Chiodini et al., “Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status,” Clinical Endocrinology, vol. 58, no. 6, pp. 725–731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. H. Kotzmann, P. Bernecker, P. Hubsch et al., “Bone mineral density and parameters of bone metabolism in patients with acromegaly,” Journal of Bone and Mineral Research, vol. 8, no. 4, pp. 459–466, 1993. View at Google Scholar · View at Scopus
  165. G. P. Lesse, W. D. Fraser, R. Farquharson, L. Hipkin, and J. P. Vora, “Gonadal status is an important determinant of bone density in acromegaly,” Clinical Endocrinology, vol. 48, no. 1, pp. 59–65, 1998. View at Publisher · View at Google Scholar · View at Scopus
  166. H. Kaji, T. Sugimoto, D. Nakaoka et al., “Bone metabolism and body composition in Japanese patients with active acromegaly,” Clinical Endocrinology, vol. 55, no. 2, pp. 175–181, 2001. View at Publisher · View at Google Scholar · View at Scopus
  167. P. J. Ho, L. M. Fig, A. L. Barkan, and B. Shapiro, “Bone mineral density of the axial skeleton in acromegaly,” Journal of Nuclear Medicine, vol. 33, no. 9, pp. 1608–1612, 1992. View at Google Scholar · View at Scopus
  168. M. J. Kayath and J. G. H. Vieira, “Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine,” Osteoporosis International, vol. 7, no. 3, pp. 226–230, 1997. View at Publisher · View at Google Scholar · View at Scopus
  169. I. Chiodini, V. Trischitta, V. Carnevale, A. Liuzzi, and A. Scillitani, “Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?” Journal of Endocrinological Investigation, vol. 24, no. 4, pp. 288–291, 2001. View at Publisher · View at Google Scholar · View at Scopus
  170. M. Bolanowski, W. Wielgus, A. Milewicz, and R. Marciniak, “Axial bone mineral density in patients with acromegaly,” Academic Radiology, vol. 7, no. 8, pp. 592–594, 2000. View at Publisher · View at Google Scholar · View at Scopus
  171. W. Zgliczynski, M. Kochman, W. Misiorowski, and P. Zdunowski, “In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender,” Neuroendocrinology Letters, vol. 28, no. 5, pp. 621–628, 2007. View at Google Scholar · View at Scopus
  172. P. Vestergaard and L. Mosekilde, “Fracture risk is decreased in acromegaly—a potential beneficial effect of growth hormone,” Osteoporosis International, vol. 15, no. 2, pp. 155–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  173. N. R. Biermasz, N. A. T. Hamdy, A. M. Pereira, J. A. Romijn, and F. Roelfsema, “Long-term maintenance of the anabolic effects of GH on the skeleton in successful treated patients with acromegaly,” European Journal of Endocrinology, vol. 152, no. 1, pp. 53–60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. P. Broulik, J. Kragstrup, L. Mosekilde, and F. Melsen, “Osteon cross-sectional size in the iliac crest. Variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia,” Acta Pathologica et Microbiologica Scandinavica A: Pathology, vol. 90, no. 5, pp. 339–344, 1982. View at Google Scholar · View at Scopus
  175. J. Halse, F. Melsen, and L. Mosekilde, “Iliac crest bone mass and remodelling in acromegaly,” Acta Endocrinologica, vol. 97, no. 1, pp. 18–22, 1981. View at Google Scholar · View at Scopus
  176. B. L. Riggs, R. V. Randall, H. W. Wahner, J. Jowsey, P. J. Kelly, and M. Singh, “The nature of the metabolic bone disorder in acromegaly.,” The Journal of Clinical Endocrinology & Metabolism, vol. 34, no. 6, pp. 911–918, 1972. View at Publisher · View at Google Scholar · View at Scopus
  177. G. Padova, G. Borzì, L. Incorvaia et al., “Prevalence of osteoporosis and vertebral fractures in acromegalic patients,” Clinical Cases in Mineral and Bone Metabolism, vol. 8, no. 3, pp. 37–43, 2011. View at Google Scholar · View at Scopus
  178. M. Madeira, L. V. Neto, F. de Paula Paranhos Neto et al., “Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1734–1741, 2013. View at Publisher · View at Google Scholar · View at Scopus
  179. T. Ueland, E. N. Ebbesen, J. S. Thomsen et al., “Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly,” European Journal of Clinical Investigation, vol. 32, no. 2, pp. 122–128, 2002. View at Publisher · View at Google Scholar · View at Scopus
  180. S. Bonadonna, G. Mazziotti, M. Nuzzo et al., “Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women,” Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1837–1844, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. G. Mazziotti, A. Bianchi, T. Porcelli et al., “Vertebral fractures in patients with acromegaly: a 3-year prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. 3402–3410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  182. K. M. Claessen, H. M. Kroon, A. M. Pereira et al., “Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study,” Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 12, pp. 4808–4815, Dec 2013. View at Publisher · View at Google Scholar
  183. G. Mazziotti, M. Gola, A. Bianchi et al., “Influence of diabetes mellitus on vertebral fractures in men with acromegaly,” Endocrine, vol. 40, no. 1, pp. 102–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. M. J. E. Wassenaar, N. R. Biermasz, N. A. T. Hamdy et al., “High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly,” European Journal of Endocrinology, vol. 164, no. 4, pp. 475–483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  185. C. Battista, I. Chiodini, S. Muscarella et al., “Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study,” Clinical Endocrinology, vol. 70, no. 3, pp. 378–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. S. Boutroy, M. L. Bouxsein, F. Munoz, and P. D. Delmas, “In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 12, pp. 6508–6515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. K. M. Nicks, S. Amin, E. J. Atkinson, B. L. Riggs, L. J. Melton III, and S. Khosla, “Relationship of age to bone microstructure independent of areal bone mineral density,” Journal of Bone and Mineral Research, vol. 27, no. 3, pp. 637–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  188. K. K. Nishiyama, H. M. Macdonald, H. R. Buie, D. A. Hanley, and S. K. Boyd, “Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study,” Journal of Bone and Mineral Research, vol. 25, no. 4, pp. 882–890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. T. Argoud, S. Boutroy, B. Claustrat, R. Chapurlat, and P. Szulc, “Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 4, pp. 1400–1410, 2014. View at Google Scholar
  190. S. J. Holmes, R. W. Whitehouse, R. Swindell, G. Economou, J. E. Adams, and S. M. Shalet, “Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency,” Clinical Endocrinology, vol. 42, no. 6, pp. 627–633, 1995. View at Publisher · View at Google Scholar · View at Scopus
  191. G. Amato, G. Izzo, G. La Montagna, and A. Bellastella, “Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects,” Clinical Endocrinology, vol. 45, no. 1, pp. 27–32, 1996. View at Publisher · View at Google Scholar · View at Scopus
  192. T. B. Hansen, K. Brixen, N. Vahl et al., “Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3352–3359, 1996. View at Publisher · View at Google Scholar · View at Scopus
  193. M. Thoren, M. Soop, M. Degerblad, and M. Saaf, “Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency,” Acta Endocrinologica,, vol. 128, supplement 2, pp. 41–43, 1993. View at Google Scholar · View at Scopus
  194. S. A. Beshyah, P. Kyd, E. Thomas, A. Fairney, and D. G. Johnston, “The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adult,” Clinical Endocrinology, vol. 42, no. 3, pp. 249–254, 1995. View at Publisher · View at Google Scholar · View at Scopus
  195. J. M. Gómez, N. Gómez, J. Fiter, and J. Soler, “Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement,” Hormone and Metabolic Research, vol. 32, no. 2, pp. 66–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  196. H. Kotzmann, M. Riedl, P. Bernecker et al., “Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency,” Calcified Tissue International, vol. 62, no. 1, pp. 40–46, 1998. View at Publisher · View at Google Scholar · View at Scopus
  197. J. Johansson, K. Landin, G. Johannsson, L. Tengborn, and B. Bengtsson, “Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults,” Thrombosis and Haemostasis, vol. 76, no. 3, pp. 422–428, 1996. View at Google Scholar · View at Scopus
  198. G. Götherström, B. A. Bengtsson, I. Bossæus, G. Johansson, and J. Svensson, “Ten-year GH replacement increase bone mineral density in hypopituitary patients with adult onset GH deficiency,” European Journal of Endocrinology, vol. 156, no. 1, pp. 55–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  199. M. Elbornsson, G. Götherström, I. Bosæus, B. Bengtsson, G. Johannsson, and J. Svensson, “Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency,” European Journal of Endocrinology, vol. 166, no. 5, pp. 787–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  200. G. Johannsson, T. Rosén, I. Bosaeus, L. Sjöström, and B. Bengtsson, “Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 8, pp. 2865–2873, 1996. View at Publisher · View at Google Scholar · View at Scopus
  201. G. Mazziotti, A. Bianchi, S. Bonadonna et al., “Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy,” Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 520–528, 2006. View at Publisher · View at Google Scholar · View at Scopus
  202. M. Barake, A. Klibanski, and N. A. Tritos, “Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. 852–860, 2014. View at Publisher · View at Google Scholar
  203. S. R. Cummings and L. J. Melton III, “Epidemiology and outcomes of osteoporotic fractures,” The Lancet, vol. 359, no. 9319, pp. 1761–1767, 2002. View at Publisher · View at Google Scholar · View at Scopus
  204. A. C. Looker, E. S. Orwoll, C. C. Johnston Jr. et al., “Prevalence of low femoral bone density in older U.S. adults from NHANES III,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1761–1768, 1997. View at Publisher · View at Google Scholar · View at Scopus
  205. Z. A. Cole, E. M. Dennison, and C. Cooper, “Osteoporosis epidemiology update,” Current Rheumatology Reports, vol. 10, no. 2, pp. 92–96, 2008. View at Google Scholar
  206. L. G. Raisz, “Pathogenesis of osteoporosis: concepts, conflicts, and prospects,” Journal of Clinical Investigation, vol. 115, no. 12, pp. 3318–3325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  207. S. Khosla and B. L. Riggs, “Pathophysiology of age-related bone loss and osteoporosis,” Endocrinology and Metabolism Clinics of North America, vol. 34, no. 4, pp. 1015–1030, 2005. View at Publisher · View at Google Scholar · View at Scopus
  208. S. Perrini, L. Laviola, M. C. Carreira, A. Cignarelli, A. Natalicchio, and F. Giorgino, “The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis,” Journal of Endocrinology, vol. 205, no. 3, pp. 201–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. E. Seeman, “Pathogenesis of bone fragility in women and men,” The Lancet, vol. 359, no. 9320, pp. 1841–1850, 2002. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Khosla, L. J. Melton III, and B. L. Riggs, “The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?” Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 441–451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  211. P. Garnero, E. Sornay-Rendu, M. C. Chapuy, and P. D. Delmas, “Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis,” Journal of Bone and Mineral Research, vol. 11, no. 3, pp. 337–349, 1996. View at Google Scholar · View at Scopus
  212. M. T. Hannan, D. T. Felson, B. Dawson-Hughes et al., “Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study,” Journal of Bone and Mineral Research, vol. 15, no. 4, pp. 710–720, 2000. View at Google Scholar · View at Scopus
  213. C. Cooper, G. Campion, and L. J. Melton III, “Hip fractures in the elderly: a world-wide projection,” Osteoporosis International, vol. 2, no. 6, pp. 285–289, 1992. View at Publisher · View at Google Scholar · View at Scopus
  214. H. Burger, P. L. A. van Daele, K. Grashuis et al., “Vertebral deformities and functional impairment in men and women,” Journal of Bone and Mineral Research, vol. 12, no. 1, pp. 152–157, 1997. View at Publisher · View at Google Scholar · View at Scopus
  215. M. Thomas-John, M. B. Codd, S. Manne, N. B. Watts, and A. Mongey, “Risk factors for the development of osteoporosis and osteoporotic fractures among older men,” Journal of Rheumatology, vol. 36, no. 9, pp. 1947–1952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  216. S. C. Manolagas, “From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis,” Endocrine Reviews, vol. 31, no. 3, pp. 266–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  217. G. A. Ledger, M. F. Burritt, P. C. Kao, W. M. O'Fallon, B. L. Riggs, and S. Khosla, “Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption,” Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 11, pp. 3304–3310, 1995. View at Google Scholar · View at Scopus
  218. V. Nicolas, A. Prewett, P. Bettica et al., “Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women: implications for bone loss with aging,” Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 5, pp. 1011–1016, 1994. View at Publisher · View at Google Scholar · View at Scopus
  219. S. Ljunghall, A. G. Johansson, P. Burman, O. Kampe, E. Lindh, and F. A. Karlsson, “Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis,” Journal of Internal Medicine, vol. 232, no. 1, pp. 59–64, 1992. View at Publisher · View at Google Scholar · View at Scopus
  220. L. Maïmoun, O. Coste, F. Galtier et al., “Bone mineral density acquisition in peripubertal female rhythmic gymnasts is directly associated with plasma IGF1/IGF-binding protein 3 ratio,” European Journal of Endocrinology, vol. 163, no. 1, pp. 157–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. S. Boonen, E. Lesaffre, J. Dequeker et al., “Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: potential implications for the prevention of age-related bone loss,” Journal of the American Geriatrics Society, vol. 44, no. 11, pp. 1301–1306, 1996. View at Google Scholar · View at Scopus
  222. C. Wuster, W. F. Blum, S. Schlemilch, M. B. Ranke, and R. Ziegler, “Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis,” Journal of Internal Medicine, vol. 234, no. 3, pp. 249–255, 1993. View at Publisher · View at Google Scholar · View at Scopus
  223. S. Khosla, E. J. Atkinson, L. J. Melton III, and B. L. Riggs, “Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 5, pp. 1522–1527, 1997. View at Google Scholar · View at Scopus
  224. J. P. T. Span, G. F. F. M. Pieters, C. G. J. Sweep, A. R. M. M. Hermus, and A. G. H. Smals, “Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: Role of sex hormone replacement,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1121–1125, 2000. View at Publisher · View at Google Scholar · View at Scopus
  225. B. C. Nindl, M. Santtila, J. Vaara, K. Hakkinen, and H. Kyrolainen, “Circulating IGF-I is associated with fitness and health outcomes in a population of 846 young healthy men,” Growth Hormone and IGF Research, vol. 21, no. 3, pp. 124–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  226. W. J. Kraemer, C. Dunn-Lewis, B. A. Comstock, G. A. Thomas, J. E. Clark, and B. C. Nindl, “Growth hormone, exercise, and athletic performance: a continued evolution of complexity,” Current Sports Medicine Reports, vol. 9, no. 4, pp. 242–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  227. S. M. Gregory, B. A. Spiering, J. A. Alemany et al., “Exercise-induced insulin-like growth factor I system concentrations after training in women,” Medicine and Science in Sports and Exercise, vol. 45, no. 3, pp. 420–428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  228. P. C. Henning, D. E. Scofield, K. R. Rarick et al., “Effects of acute caloric restriction compared to caloric balance on the temporal response of the IGF-I system,” Metabolism: Clinical and Experimental, vol. 62, no. 2, pp. 179–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  229. T. Chevalley, P. Hoffmeyer, J. Bonjour, and R. Rizzoli, “Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture,” Clinical Nutrition, vol. 29, no. 1, pp. 78–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  230. A. L. Darling, D. J. Millward, D. J. Torgerson, C. E. Hewitt, and S. A. Lanham-New, “Dietary protein and bone health: a systematic review and meta-analysis,” The American Journal of Clinical Nutrition, vol. 90, no. 6, pp. 1674–1692, 2009. View at Publisher · View at Google Scholar · View at Scopus
  231. C. Franceschi, M. Bonafè, S. Valensin et al., “Inflamm-aging. An evolutionary perspective on immunosenescence,” Annals of the New York Academy of Sciences, vol. 908, pp. 244–254, 2000. View at Google Scholar · View at Scopus
  232. M. S. Nanes, “Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology,” Gene, vol. 321, no. 1-2, pp. 1–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  233. E. C. Wahl, J. Aronson, L. Liu et al., “Restoration of regenerative osteoblastogenesis in aged mice: modulation of TNF,” Journal of Bone and Mineral Research, vol. 25, no. 1, pp. 114–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  234. S. Boonen, E. Lesaffre, J. Aerssens, W. Pelemans, J. Dequeker, and R. Bouillon, “Deficiency of the growth hormone-insulin-like growth factor-1 axis potentially involved in age-related alterations in body composition,” Gerontology, vol. 42, no. 6, pp. 330–338, 1996. View at Publisher · View at Google Scholar · View at Scopus
  235. J. D. Veldhuis and C. Y. Bowers, “Human GH pulsatility: an ensemble property regulated by age and gender,” Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 799–813, 2003. View at Publisher · View at Google Scholar · View at Scopus
  236. C. A. Benbassat, K. C. Maki, and T. G. Unterman, “Circulating levels of insulin-like growth factor (IGF) binding protein- 1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 5, pp. 1484–1491, 1997. View at Google Scholar · View at Scopus
  237. M. Nasu, T. Sugimoto, M. Chihara, M. Hiraumi, F. Kurimoto, and K. Chihara, “Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: Relationship with bone mineral density and lipid metabolism in perimenopausal women,” European Journal of Endocrinology, vol. 136, no. 6, pp. 608–616, 1997. View at Publisher · View at Google Scholar · View at Scopus
  238. E. Romagnoli, S. Minisola, V. Carnevale et al., “Circulating levels of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor I (IGF-I) in perimenopausal women,” Osteoporosis International, vol. 4, no. 6, pp. 305–308, 1994. View at Publisher · View at Google Scholar · View at Scopus
  239. M. Muñoz-Torres, P. Mezquita-Raya, F. Lopez-Rodriguez, E. Torres-Vela, J. de Dios Luna, and F. Escobar-Jimenez, “The contribution of IGF-I to skeletal integrity in postmenopausal women,” Clinical Endocrinology, vol. 55, no. 6, pp. 759–766, 2001. View at Publisher · View at Google Scholar · View at Scopus
  240. P. Gillberg, H. Olofsson, H. Mallmin, W. F. Blum, S. Ljunghall, and A. G. Nilsson, “Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men,” Calcified Tissue International, vol. 70, no. 1, pp. 22–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  241. H. P. Kruse and F. Kuhlencordt, “On an attempt to treat primary and secondary osteoporosis with human growth hormone,” Hormone and Metabolic Research, vol. 7, no. 6, pp. 488–491, 1975. View at Publisher · View at Google Scholar · View at Scopus
  242. K. Brixen, H. K. Nielsen, L. Mosekilde, and A. Flyvbjerg, “A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers,” Journal of Bone and Mineral Research, vol. 5, no. 6, pp. 609–618, 1990. View at Google Scholar · View at Scopus
  243. D. Rudman, A. G. Feller, H. S. Nagraj et al., “Effects of human growth hormone in men over 60 years old,” The New England Journal of Medicine, vol. 323, no. 1, pp. 1–6, 1990. View at Publisher · View at Google Scholar · View at Scopus
  244. L. Holloway, G. Butterfield, R. L. Hintz, N. Gesundheit, and R. Marcus, “Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women,” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 2, pp. 470–479, 1994. View at Publisher · View at Google Scholar · View at Scopus
  245. T. Bianda, M. A. Hussain, Y. Glatz, R. Bouillon, E. R. Froesch, and C. Schmid, “Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man,” Journal of Internal Medicine, vol. 241, no. 2, pp. 143–150, 1997. View at Publisher · View at Google Scholar · View at Scopus
  246. B. Clemmesen, K. Overgaard, B. Riis, and C. Christiansen, “Human growth hormone and growth hormone releasing hormone: a double-masked, placebo-controlled study of their effects on bone metabolism in elderly women,” Osteoporosis International, vol. 3, no. 6, pp. 330–336, 1993. View at Publisher · View at Google Scholar · View at Scopus
  247. M. Kassem, K. Brixen, W. Blum, L. Mosekilde, and E. F. Eriksen, “No evidence for reduced spontaneous or growth-hormone-stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis,” European Journal of Endocrinology, vol. 131, no. 2, pp. 150–155, 1994. View at Publisher · View at Google Scholar · View at Scopus
  248. R. J. Erdtsieck, H. A. P. Pols, N. K. Valk et al., “Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial,” Clinical Endocrinology, vol. 43, no. 5, pp. 557–565, 1995. View at Publisher · View at Google Scholar · View at Scopus
  249. L. Holloway, L. Kohlmeier, K. Kent, and R. Marcus, “Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 4, pp. 1111–1117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  250. M. Kassem, K. Brixen, L. Mosekilde, W. F. Blum, and A. Flyvbjerg, “Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women,” Clinical Endocrinology, vol. 49, no. 6, pp. 747–756, 1998. View at Publisher · View at Google Scholar · View at Scopus
  251. T. Sugimoto, D. Nakaoka, M. Nasu, M. Kanzawa, T. Sugishita, and K. Chihara, “Effect of recombinant human growth hormone in elderly osteoporotic women,” Clinical Endocrinology, vol. 51, no. 6, pp. 715–724, 1999. View at Publisher · View at Google Scholar · View at Scopus
  252. M. Sääf, A. Hilding, M. Thorén, S. Troell, and K. Hall, “Growth hormone treatment of osteoporotic postmenopausal women—a one-year placebo-controlled study,” European Journal of Endocrinology, vol. 140, no. 5, pp. 390–399, 1999. View at Publisher · View at Google Scholar · View at Scopus
  253. T. Sugimoto, H. Kaji, D. Nakaoka et al., “Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis,” European Journal of Endocrinology, vol. 147, no. 3, pp. 339–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  254. P. Gillberg, H. Mallmin, M. Petrén-Mallmin, S. Ljunghall, and A. G. Nilsson, “Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 11, pp. 4900–4906, 2002. View at Publisher · View at Google Scholar · View at Scopus
  255. K. Landin-Wilhelmsen, A. Nilsson, I. Bosaeus, and B. Bengtsson, “Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial,” Journal of Bone and Mineral Research, vol. 18, no. 3, pp. 393–405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  256. F. Joseph, A. M. Ahmad, M. Ul-Haq et al., “Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis,” Journal of Bone and Mineral Research, vol. 23, no. 5, pp. 721–729, 2008. View at Publisher · View at Google Scholar · View at Scopus
  257. A. G. Johansson, E. Lindh, W. F. Blum, G. Kollerup, O. H. Sørensen, and S. Ljunghall, “Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 1, pp. 44–48, 1996. View at Publisher · View at Google Scholar · View at Scopus
  258. H. D. White, A. M. Ahmad, B. H. Durham et al., “Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3371–3380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  259. K. K. Y. Ho and A. J. Weissberger, “Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism,” Journal of Bone and Mineral Research, vol. 7, no. 7, pp. 821–827, 1992. View at Google Scholar · View at Scopus
  260. R. Marcus, G. Butterfield, L. Holloway et al., “Effects of short term administration of recombinant human growth hormone to elderly people,” Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 2, pp. 519–527, 1990. View at Publisher · View at Google Scholar · View at Scopus
  261. T. L. Bianda, “Effects of growth hormone (GH) and insulin-like growth factor-I on serum leptin in GH-deficient adults,” Diabetologia, vol. 40, no. 3, pp. 363–364, 1997. View at Google Scholar · View at Scopus
  262. A. G. Johansson, E. Lindh, and S. Ljunghall, “Insulin-like growth factor I stimulates bone turnover in osteoporosis,” The Lancet, vol. 339, no. 8809, article 1619, 1992. View at Google Scholar · View at Scopus
  263. P. R. Ebeling, J. D. Jones, W. M. O'Fallon, C. H. Janes, and B. L. Riggs, “Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women,” Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 5, pp. 1384–1387, 1993. View at Publisher · View at Google Scholar · View at Scopus
  264. C. D. Rubin, B. Reed, K. Sakhaee, and C. Y. C. Pak, “Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin-like growth factor,” Annals of Internal Medicine, vol. 121, no. 9, pp. 665–668, 1994. View at Publisher · View at Google Scholar · View at Scopus
  265. S. K. Grinspoon, H. B. A. Baum, S. Peterson, and A. Klibanski, “Effects of rhIGF-I administration on bone turnover during short-term fasting,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 900–906, 1995. View at Publisher · View at Google Scholar · View at Scopus
  266. L. J. Ghiron, J. L. Thompson, L. Holloway et al., “Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women,” Journal of Bone and Mineral Research, vol. 10, no. 12, pp. 1844–1852, 1995. View at Google Scholar · View at Scopus
  267. S. Grinspoon, H. Baum, K. Lee, E. Anderson, D. Herzog, and A. Klibanski, “Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 11, pp. 3864–3870, 1996. View at Publisher · View at Google Scholar · View at Scopus
  268. N. Mauras, S. Q. Doi, and J. R. Shapiro, “Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 6, pp. 2222–2226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  269. A. L. Friedlander, G. E. Butterfield, S. Moynihan et al., “One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 4, pp. 1496–1503, 2001. View at Publisher · View at Google Scholar · View at Scopus
  270. S. Boonen, C. Rosen, R. Bouillon et al., “Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 4, pp. 1593–1599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  271. S. Grinspoon, L. Thomas, K. Miller, D. Herzog, and A. Klibanski, “Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 6, pp. 2883–2891, 2002. View at Publisher · View at Google Scholar · View at Scopus
  272. S. Grinspoon, K. Miller, D. Herzog, D. Clemmons, and A. Klibanski, “Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1142–1149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  273. M. Misra, J. McGrane, K. K. Miller et al., “Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa,” Bone, vol. 45, no. 3, pp. 493–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  274. A. J. van der Lely, S. W. Lamberts, K. W. Jauch et al., “Use of human GH in elderly patients with accidental hip fracture,” European Journal of Endocrinology, vol. 143, no. 5, pp. 585–592, 2000. View at Publisher · View at Google Scholar · View at Scopus
  275. A.-L. Yeo, D. Levy, F. C. Martin et al., “Frailty and the biochemical effects of recombinant human growth hormone in women after surgery for hip fracture,” Growth Hormone and IGF Research, vol. 13, no. 6, pp. 361–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  276. A. J. Weissberger, A. D. Anastasiadis, I. Sturgess, F. C. Martin, M. A. Smith, and P. H. Sönksen, “Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement,” Clinical Endocrinology, vol. 58, no. 1, pp. 99–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  277. M. Hedström, M. Sääf, E. Brosjö et al., “Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fracture: a double-blind placebo-controlled pilot study in 20 patients,” Acta Orthopaedica Scandinavica, vol. 75, no. 4, pp. 394–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  278. M. Raschke, M. Højby Rasmussen, S. Govender, D. Segal, M. Suntum, and J. S. Christiansen, “Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial,” European Journal of Endocrinology, vol. 156, no. 3, pp. 341–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  279. T. Krusenstjerna-Hafstrøm, M. H. Rasmussen, M. Raschke, S. Govender, J. Madsen, and J. S. Christiansen, “Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections. Implications for detection of GH abuse,” Growth Hormone and IGF Research, vol. 21, no. 6, pp. 331–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  280. A. G. Johansson, E. Lindh, G. Kollerup, and S. Ljunghal, “Dose-dependent of IGF-1 on the metabolism of collagen type I in male osteoporosis,” Journal of Bone and Mineral Research, vol. 10, article S393, 1995. View at Google Scholar
  281. A. V. Papavasiliou, “Histological and biological changes in the epiphyseal plate during fracture healing,” Journal of Orthopaedic Science, vol. 7, no. 1, pp. 91–96, 2002. View at Publisher · View at Google Scholar · View at Scopus
  282. M. A. Mont, L. C. Jones, T. A. Einhorn, D. S. Hungerford, and A. H. Reddi, “Osteonecrosis of the femoral head: potential treatment with growth and differentiation factors,” Clinical Orthopaedics and Related Research, no. 355, pp. S314–S335, 1998. View at Google Scholar · View at Scopus
  283. S. N. Lissenberg-Thunnissen, D. J. J. de Gorter, C. F. M. Sier, and I. B. Schipper, “Use and efficacy of bone morphogenetic proteins in fracture healing,” International Orthopaedics, vol. 35, no. 9, pp. 1271–1280, 2011. View at Publisher · View at Google Scholar · View at Scopus
  284. H. Bail, M. J. Raschke, S. F. Kolbeck, A. Weiler, P. M. Haahr, and N. P. Haas, “Recombinant growth hormone increasus callus maturation time in distraction osteogenesis—a histomorphometric study,” Langenbecks Archiv für Chirurgie, vol. 115, supplement I, pp. 675–680, 1998. View at Google Scholar · View at Scopus
  285. S. D. Cook, G. C. Baffes, M. W. Wolfe, T. K. Sampath, D. C. Rueger, and T. S. Whitecloud III, “The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects,” Journal of Bone and Joint Surgery A, vol. 76, no. 6, pp. 827–838, 1994. View at Google Scholar · View at Scopus
  286. H. Kawaguchi, T. Kurokawa, K. Hanada et al., “Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats,” Endocrinology, vol. 135, no. 2, pp. 774–781, 1994. View at Publisher · View at Google Scholar · View at Scopus
  287. H. M. Nielsen, B. Bak, P. H. Jorgensen, and T. T. Andreassen, “Growth hormone promotes healing of tibial fractures in the rat,” Acta Orthopaedica Scandinavica, vol. 62, no. 3, pp. 244–247, 1991. View at Publisher · View at Google Scholar · View at Scopus
  288. T. J. Nash, C. R. Howlett, C. Martin, J. Steele, K. A. Johnson, and D. J. Hicklin, “Effect of platelet-derived growth factor on tibial osteotomies in rabbits,” Bone, vol. 15, no. 2, pp. 203–208, 1994. View at Publisher · View at Google Scholar · View at Scopus
  289. R. F. Spencer, “The effect of head injury on fracture healing. A quantitative assessment,” Journal of Bone and Joint Surgery B, vol. 69, no. 4, pp. 525–528, 1987. View at Google Scholar · View at Scopus
  290. S. M. Bidner, I. M. Rubins, J. V. Desjardins, D. J. Zukor, and D. Goltzman, “Evidence for a humoral mechanism for enhanced osteogenesis after head injury,” Journal of Bone and Joint Surgery, vol. 72, no. 8, pp. 1144–1149, 1990. View at Google Scholar · View at Scopus
  291. D. Gazit, M. Karmish, L. Holzman, and I. Bab, “Regenerating marrow induces systemic increase in osteo- and chondrogenesis,” Endocrinology, vol. 126, no. 5, pp. 2607–2613, 1990. View at Publisher · View at Google Scholar · View at Scopus
  292. S. Weiss, P. Henle, M. Bidlingmaier, A. Moghaddam, P. Kasten, and G. Zimmermann, “Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing,” Growth Hormone and IGF Research, vol. 18, no. 3, pp. 205–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  293. M. di Monaco, F. Vallero, R. Di Monaco, R. Tappero, and A. Cavanna, “Serum levels of insulin-like growth factor-I are positively associated with functional outcome after hip fracture in elderly women,” The American Journal of Physical Medicine and Rehabilitation, vol. 88, no. 2, pp. 119–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  294. G. Johannsson and C. Ohlsson, “Growth hormone therapy and fracture risk in the growth hormone-deficient adult,” Bailliere's Clinical Endocrinology and Metabolism, vol. 12, no. 2, pp. 233–250, 1998. View at Publisher · View at Google Scholar · View at Scopus
  295. S. Yang, L. Cao, S. Cai, J. Yuan, and J. Wang, “A systematic review of growth hormone for hip fractures,” Growth Hormone and IGF Research, vol. 22, no. 3-4, pp. 97–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  296. B. R. Bistrian, J. Schwartz, and N. W. Istfan, “Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation,” Proceedings of the Society for Experimental Biology and Medicine, vol. 200, no. 2, pp. 220–223, 1992. View at Publisher · View at Google Scholar · View at Scopus
  297. D. W. Wilmore, “Catabolic illness: Strategies for enhancing recovery,” The New England Journal of Medicine, vol. 325, no. 10, pp. 695–702, 1991. View at Publisher · View at Google Scholar · View at Scopus
  298. R. N. Cooney and M. Shumate, “The inhibitory effects of interleukin-1 on growth hormone action during catabolic illness,” Vitamins & Hormones, vol. 74, pp. 317–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  299. S. von Laue and R. J. M. Ross, “Inflammatory cytokines and acquired growth hormone resistance,” Growth Hormone and IGF Research, vol. 10, S9, p. S14, 2000. View at Publisher · View at Google Scholar · View at Scopus
  300. G. Yumet, M. L. Shumate, D. P. Bryant, C. H. Lang, and R. N. Cooney, “Hepatic growth hormone resistance during sepsis is associated with increased suppressors of cytokine signaling expression and impaired growth hormone signaling,” Critical Care Medicine, vol. 34, no. 5, pp. 1420–1427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  301. G. Yumet, M. L. Shumate, P. Bryant, C. Lin, C. H. Lang, and R. N. Cooney, “Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis,” American Journal of Physiology: Endocrinology and Metabolism, vol. 283, no. 3, pp. E472–E481, 2002. View at Google Scholar · View at Scopus
  302. T. A. Ahmed, M. D. Buzzelli, C. H. Lang et al., “Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes,” American Journal of Physiolog: Gastrointestinal and Liver Physiology, vol. 292, no. 6, pp. G1793–G1803, 2007. View at Publisher · View at Google Scholar · View at Scopus
  303. A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt, “The role of the IGF system in cancer growth and metastasis: overview and recent insights,” Endocrine Reviews, vol. 28, no. 1, pp. 20–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  304. E. Seccareccia and P. Brodt, “The role of the insulin-like growth factor-I receptor in malignancy: an update,” Growth Hormone & IGF Research, vol. 22, no. 6, pp. 193–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  305. A. Deodati, B. B. Ferroli, and S. Cianfarani, “Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis,” Growth Hormone and IGF Research, 2014. View at Publisher · View at Google Scholar
  306. J. C. Carel, E. Ecosse, F. Landier et al., “Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 416–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  307. L. Sävendahl, M. Maes, K. Albertsson-Wikland et al., “Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: Preliminary report of 3 countries participating in the EU SAGhE study,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. E213–E217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  308. S. Pekic and V. Popovic, “GH therapy and cancer risk in hypopituitarism: what we know from human studies,” European Journal of Endocrinology, vol. 169, no. 5, pp. R89–R97, 2013. View at Google Scholar
  309. B. Ergun-Longmire, A. C. Mertens, P. Mitby et al., “Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3494–3498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  310. V. Popovic, A. F. Mattsson, R. C. Gaillard, P. Wilton, M. Kołtowska-Häggström, and M. B. Ranke, “Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database),” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4449–4454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  311. H. Xiang, Y. Wang, and S. Nie, “Meta-analysis of the association between insulin-like growth factor binding protein 3 genetic polymorphisms and colorectal cancer susceptibility,” PLoS ONE, vol. 8, no. 3, Article ID e59665, 2013. View at Publisher · View at Google Scholar · View at Scopus
  312. K. Chihara, Y. Kato, H. Kohno et al., “Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD),” Growth Hormone and IGF Research, vol. 18, no. 4, pp. 307–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  313. N. Mauras, A. D. Rogol, M. W. Haymond, and J. D. Veldhuis, “Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty,” Hormone Research, vol. 45, no. 1-2, pp. 74–80, 1996. View at Google Scholar · View at Scopus
  314. S. Khosla, L. J. Melton, and B. L. Riggs, “Estrogens and bone health in men,” Calcified Tissue International, vol. 69, no. 4, pp. 189–192, 2001. View at Publisher · View at Google Scholar · View at Scopus